Tromsø, Norway, May 8[th], 2024 - ArcticZymes Technologies (OSE: AZT) reported
sales of NOK 30.0 million and an EBITDA of NOK 2.3 million for the first quarter
of 2024.

Highlights from Q1

  · ArcticZymes Technologies (AZT) had Q1 sales of NOK 30.0 million (Q1 2023:
NOK 31.2 million
  · AZT had a positive EBITDA for Q1 of NOK 2.3 million (Q1 2023: NOK 6.1
million) and a net profit of NOK 3.2 million (Q1 2023: NOK 5.0 million)
  · Operating expenses for Q1 were 27.7 million (Q1 2023: NOK 25.1 million)
where extraordinary items related to closing of Oslo office accounted for NOK
0.8 million and implementation of a new ERP solution accounted for NOK 1.5
million.
  · Cash flow for Q1 was negative NOK -7.9 million (Q1 2023: NOK -12.5 million)
explained by increase in receivables by NOK -6.9 million and investment in
intangibles of NOK -4.0 million, giving a cash balance of NOK 173.0 million. In
addition, NOK 70 million is invested in low-risk interest rate funds.
  · Launch of SAN HQ GMP
  · New Research partnership with Austrian Center of Biotechnoloy (acib) to
generate SAN benchmarking data, posters and publications - supported by COMET
(Competence Centers for Excellent Technologies) grant funding with EUR 100 000

CEO Michael B. Akoh comments:

In Q1, we successfully introduced SAN HQ GMP, ArcticZymes' first GMP grade
enzyme with product availability in March. This milestone is an important
building block enabling us to serve more customers in the biomanufacturing
segment. I was also pleased to see the initiation of a research project with
acib that will provide further important data on the performance of our SAN
portfolio.

We expect that market conditions will continue to be challenging in Q2 with a
potential for gradual improvement in the latter half of the year, as previously
discussed. We will continue to strengthen our product portfolio and
commercialization of our novel enzymes.

-Ends-

Presentation and Webcast
The Company will host a virtual Q1 2024 presentation for investors, analysts and
media at 08:30 CET on Wednesday, May 8th, 2024.

The presentation will be given by CEO, Michael Akoh, CFO, Børge Sørvoll.

The presentation can be followed as a live webcast from Hegnar TV on:
https://channel.royalcast.com/landingpage/hegnarmedia/20240508_3/ or
www.arcticzymes.com. It will be possible to post questions through the webcast
console.

The report for Q1 2024 will be available on www.newsweb.no and on the company's
homepage www.arcticzymes.com from 07.00 CET on Wednesday, 8 May, 2024.

For more information, please contact:

ArcticZymes Technologies ASA
CEO, Michael B. Akoh              Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll                     Tel: +47 95 29 01 87


About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [AZT] ticker.
Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com